title: Molecular biological design of novel antineoplastic therapies.
abstract: Novel therapies represent a new strategy for the development of anticancer agents. New targets derived from the knowledge of the molecular structure and genetic defects has been useful in developing anticancer drugs that prolong or stabilise the progression of tumours with minimal systemic toxicities. In this review, the mechanism of action and the most significant trials regarding monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis and cyclooxygenase inhibitor-based therapies, farnesyl transferase inhibitors and proteasome inhibitors are discussed. The potential biological end points and toxicities are also described. In conclusion, novel therapies present a promising class of anticancer agents, acting through different mechanisms and offering a new perspective in the treatment of cancer.
authors.affiliation: Emory University School of Medicine and Winship Cancer Institute, Crawford Long Hospital, 550 Peachtree Street, Glenn Building, Atlanta, GA, USA.
authors.forename: Michel
authors.initials: M
authors.lastname: Vulfovich
authors.forename: Nabil
authors.initials: N
authors.lastname: Saba
mesh_terms: D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003546:Cysteine Endopeptidases; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D051231:Farnesyltranstransferase; D006801:Humans; D008967:Molecular Biology; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy; D046988:Proteasome Endopeptidase Complex; D015398:Signal Transduction; D018631:ras Proteins / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D018631:ras Proteins